Global Cancer Immunotherapy Market

Global Cancer Immunotherapy Market Size, Share, Growth Analysis, By Product(Monoclonal Antibodies, Immunomodulators), By Cancer Type(Lung Cancer, Breast Cancer), By End-User(Hospitals, Homecare), By Route of Administration(Oral, Parenteral) - Industry Forecast 2023-2030

Report ID: SQSG35I2045 | Region: Global | Published Date: December, 2022 | Pages: 157 | Tables: 120 | Figures: 77

To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
$5,300
BUY NOW
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

Cancer Immunotherapy Market size was valued at USD 39.05 billion in 2021 and is poised to grow from USD 85.6 billion in 2022 to USD 309.67 billion by 2030, growing at a CAGR of 9.6% in the forecast period (2023-2030).

Global cancer immunotherapy market is highly competitive with the existence of several large pool players operating around the globe. The major players of the global market are focusing on few business developing strategies including high investment in research & development activities, increasing product innovation, strategic partnerships, and collaborations for the expansion of their geographical presence and strengthen their market position among competitors. 'Amgen Inc.', 'AstraZeneca Plc', 'Bristol-Myers Squibb Company', 'F. Hoffmann-La Roche Ltd', 'Gilead Sciences, Inc.', 'GlaxoSmithKline plc', 'Johnson & Johnson', 'Merck & Co., Inc.', 'Novartis International AG', 'Pfizer Inc.', 'Sanofi S.A.', 'AbbVie Inc.', 'Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company)', 'Eli Lilly and Company', 'Incyte Corporation', 'Kite Pharma, Inc. (a subsidiary of Gilead Sciences, Inc.)', 'MedImmune, LLC (a subsidiary of AstraZeneca Plc)', 'Neon Therapeutics, Inc.', 'Seattle Genetics, Inc.', 'Takeda Pharmaceutical Company Limited'

High Efficacy of Immunotherapy to Boost Market Growth

Approval of New Drug Class to Surge Market Growth

Globally, North America dominated the cancer immunotherapy market with a healthy market share in 2021 due to the rising incidence of diseases, adoption to high technology devices, and growing geriatric population. Additionally, growing number of biotechnology companies and continuously rising development activities coupled with the high consumer income, are some other factors projected to drive the growth of the market in the region over the coming years.

Related Reports

Global Cancer Immunotherapy Market

Report ID: UCMIG35I2009 | Region: Global | Published Date: December, 2022 | Pages: 165 | Tables: Figures:

HVAC Filters Market
Buy Now Get Sample
Global Cancer Immunotherapy Market

Report ID: UCMIG35I2153 | Region: Global | Published Date: December, 2022 | Pages: 165 | Tables: Figures:

Artemisinin Market
Buy Now Get Sample
Global Cancer Immunotherapy Market

Report ID: SQSG35I2014 | Region: Global | Published Date: December, 2022 | Pages: 157 | Tables: 66 | Figures: 75

Global Hyperphosphatemia Therapeutics Market
Buy Now Get Sample
Global Cancer Immunotherapy Market

Report ID: UCMIG35I2258 | Region: Global | Published Date: December, 2022 | Pages: 165 | Tables: Figures:

Antimalarial Drugs Market
Buy Now Get Sample

Feedback From Our Clients

Global Cancer Immunotherapy Market

Product ID: SQSG35I2045

$5,300
BUY NOW